DUBLIN, September 23, 2022 /PRNewswire/ — The Global Markets for Insulin Drugs and Delivery Technologies report has been added to the ResearchAndMarkets.com supply.
This report will provide an in-depth insight into the Insulin Drug and Delivery Technology market. This report analyzes insulin drug and delivery technology market trends with data from 2021, forecasts from 2022, CAGR forecasts to 2027 (forecast period 2022-2027) and regional insulin drug markets drugs and delivery technologies.
This report will highlight the current and future market potential of insulin drugs and delivery technologies along with a detailed analysis of the competitive landscape. Regulatory scenarios, incentives, constraints and opportunities will be covered in this report. The report also covers market forecasts to 2026 and market share for key market players.
Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Appropriate insulin delivery devices, such as smart pens, help diabetes patients optimize blood sugar control and minimize the risk of related complications. health issues. Advanced insulin delivery devices offer better patient compliance.
Traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens due to the latter’s portability, greater dosing accuracy, built-in memory, larger doses, and ease of use. There is no major breakthrough in traditional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd. Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Key manufacturers of advanced insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon, and Viatris Inc.
Market growth is driven by factors such as increasing incidence of diabetes and new insulin drugs and delivery technologies. The global insulin drug and delivery technology market is segmented by device type, insulin type, and region.
In this report, the market is segmented on the basis of device type, insulin type, and geographical region. Device types include syringes, insulin pens, insulin pumps, smart pens, and more. Insulin types include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting insulins.
Geographical regions covered include North America, Europe, Asia-Pacific region and the rest of the world (RoW). Individual countries covered include the US, GermanyUnited Kingdom, Italy, France, Japan, China and India.
Descriptive company profiles of key manufacturers of advanced insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
The report includes
- 24 data tables and 31 supplementary tables
- An up-to-date overview of the global markets for insulin drugs and delivery technologies
- Global market trend analyzes with historical market revenue (sales data) 2020 and 2021, forecasts to 2022 and CAGR forecasts to 2027.
- Highlights of the current status of the Insulin Drug and Delivery industry structure, new technological updates and issues related to Insulin Pens and Insulin Syringes, current research activities and regulatory and pricing scenarios
- Actual market size estimation and market forecast for insulin drugs and delivery technologies and corresponding market share analysis by device type, insulin type and geographic region
- Updated information on key M&A deals, partnerships, collaborations and other strategic alliances in the insulin drug and delivery technology industry
- Market opportunity analysis with a holistic overview of the Porter’s Five Forces analysis model, taking into account both the micro and macro environmental factors prevailing in the market
- Identification of key stakeholders and analysis of the competitive landscape based on recent developments and segment revenues
Main topics covered:
Chapter 1 Introduction
1.1 Overview of insulin
1.2 Overview of diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Aims and objectives of the research
1.4 Reasons for conducting this survey
1.5 What’s new in this update?
1.6 Scope of the report
1.7 Sources of Information
1.9 Geographical Breakdown
1.10 Analyst Credentials
1.11 Custom Survey
1.12 Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market dynamics
3.1 Market Drivers
3.1.1 Increasing prevalence of diabetes
3.1.2 Intelligent insulin drug delivery technologies
3.1.3 Technologies for painless delivery of insulin drugs
3.2 Market Restrictions
3.2.1 Downloading Products
3.3 Market Opportunities
3.3.1 Inorganic strategies among market participants
Chapter 4 Market Overview
4.1 Market Insights
4.2 Current Market Trends
4.2.1 Recent Product Introductions
4.2.2 Recent strategic alliances
4.3 Future Outlook
Chapter 5 Regulatory landscape and reimbursement scenario
5.1 Regulatory landscape
5.1.1 US Medical Device Regulations
5.1.2 US Drug Regulations
5.1.3 European regulations for medical devices
5.1.4 European Medicines Regulations
5.1.5 Asia Pacific Medical Device Regulations
5.2 Recovery Scenario
5.2.1 Pricing and Refund Review
5.2.2 Pricing and Reimbursement of Medical Devices
5.2.3 Pricing and Reimbursement of Pharmaceutical Products
5.3.1 Diabetes Emergency Insurance
Chapter 6 Impact of Covid-19 on the Market
6.2 Covid-19 Crisis
6.2.1 Market Impact on Insulin Drugs and Delivery Technologies
6.2.2 Measures for Covid-19
Chapter 7 Market Breakdown by Device Type
7.1 Insulin Delivery Technologies
7.1.2 Insulin pens
7.1.3 Insulin pumps
7.1.4 Smart Pens
Chapter 8 Market Breakdown by Type of Insulin
8.1.1 Structure of insulin
8.1.2 Biosynthesis of insulin
8.1.3 Types of insulin
Chapter 9 Market Breakdown by Regions
9.1.1 North America
9.1.3 Asia-Pacific region
9.1.4 Rest of the world
Chapter 10 Market Opportunity Analysis
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition
Chapter 11 Competitive landscape
Chapter 12 Company Profiles
12.1 Principal Companies
- B. Braun Melsungen AG
- Becton, Dickinson and Co.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Medtronic Inc.
- Novo Nordisk A/S
- Viatris Inc.
- Ypsomed Holding AG
- Other companies
- Cequr Simplicity
- Debiotech Sa
- Emperra GmbH Technologies for eHealth
- Insulet Corp.
- Nanopass Technologies Ltd.
- Nipro Medical Corp.
- Owen Mumford Ltd.
- Tandem Diabetes Care Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/qw0qyx
Research and Markets
Laura WoodSenior Manager
For EST hours Call +1-917-300-0470
For USA/Canada Call Toll Free +1-800-526-8630
For GMT business hours Call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside USA): +353-1-481-1716
SOURCE Research and Markets